Tanvex BioPharma Inc (6541) — Cash Flow-to-Debt Ratio

Latest as of March 2026: -0.14x

Tanvex BioPharma Inc (6541) has a Cash Flow-to-Debt Ratio of -0.14x as of March 2026, meaning its operating cash flow of NT$-309.37 Million could theoretically repay 0% of its total liabilities (NT$2.27 Billion) in one year. See 6541 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.

CF-to-Debt Ratio

-0.14x
Operating CF / Total Liabilities

Operating Cash Flow

NT$-309.37 Million
TWD

Total Liabilities

NT$2.27 Billion
TWD

Data as of

Mar 2026
Most recent filing

Tanvex BioPharma Inc Cash Flow-to-Debt Ratio (2013–2025)

Historical debt coverage capacity for Tanvex BioPharma Inc across 13 annual periods. For the full cash flow conversion analysis, see Tanvex BioPharma Inc cash conversion from operations.

Annual Cash Flow-to-Debt Ratio for Tanvex BioPharma Inc (2013–2025)

Year-by-year debt coverage analysis for Tanvex BioPharma Inc.

Year CF-to-Debt Ratio Operating CF (TWD) Total Liabilities YoY Change
2025 -0.44x NT$-1.01 Billion NT$2.27 Billion ▲ +29.0%
2024 -0.62x NT$-1.15 Billion NT$1.84 Billion ▲ +15.4%
2023 -0.74x NT$-1.43 Billion NT$1.94 Billion ▼ -12.3%
2022 -0.66x NT$-1.33 Billion NT$2.03 Billion ▲ +9.0%
2021 -0.72x NT$-1.39 Billion NT$1.92 Billion ▲ +29.2%
2020 -1.02x NT$-1.79 Billion NT$1.75 Billion ▲ +70.9%
2019 -3.50x NT$-1.90 Billion NT$542.12 Million ▲ +42.4%
2018 -6.08x NT$-1.61 Billion NT$263.92 Million ▼ -12.3%
2017 -5.42x NT$-1.21 Billion NT$223.78 Million ▼ -94.5%
2016 -2.79x NT$-833.43 Million NT$299.25 Million ▲ +50.6%
2015 -5.64x NT$-684.20 Million NT$121.41 Million ▲ +15.5%
2014 -6.67x NT$-434.17 Million NT$65.09 Million ▼ -132.5%
2013 -2.87x NT$-239.86 Million NT$83.63 Million —
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.